



# Keiji Tanese

M.D., Ph.D.

## Current Appointments

Assistant Professor, Department of Dermatology

Keio University School of Medicine

## Education and Training

### University:

1995-2001 MD, Keio University School of Medicine

2003-2007 PhD course in Department of Dermatology and Pathology

Keio University, Graduate School of Medicine

2009 PhD received.

### Residency:

2001 Resident in Dermatology,

National hospital organization Tokyo Medical Center

2002-2003 Resident in Dermatology

Keio University School of Medicine

## Expertise

- Dermatopathology
- Oncology
- Drug regulatory science
- Atopic dermatitis
- Psoriasis

## Fellowship Appointments

2007-2009 Fellow in Dermatology,

Kawasaki municipal hospital

2010 Postdoctoral fellow in Department of Experimental Therapeutics

## Keiji Tanese

	University of Texas MD Anderson Cancer Center
2011-2012	Postdoctoral fellow in Department of Melanoma Medical Oncology University of Texas MD Anderson Cancer Center
2013-	Assistant Professor Department of Dermatology Keio University School of Medicine
2016-2019	Reviewer, Pharmaceutical and Medical Device Agency

### Awards and Honors

2019	Certificate of Appreciation for Dispatch to Public Organizations (from Japanese Dermatological Association)
------	--

### Medical Societies

2001-present	Japanese Dermatological Association
2004-present	Japanese Cancer Association
2005-present	Japanese Skin Cancer Society
2007-present	Japanese Society for Investigative Dermatology
2013-present	Japanese Dermatohistopathology Society

### Selected 10 Publications

**(Over 70 publications; total citation 643; h-index 13; ORCID 0000-0002-1409-6475)**

1. Tanese K, Fukuma M, Yamada T, Mori T, Yoshikawa T, Watanabe W, Ishiko A, Amagai M, Nishikawa T, Sakamoto M: G-protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation. **Am J Pathol 173(3):835-843,2008.**
2. Tanese K, Grimm EA, Ekmekcioglu S: The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10. **Int J Can 131(4):891-901, 2012.**
3. Tanese K, Niizeki H, Seki A, Otsuka A, Kabashima K, Kosaki K, Kuwahara M, Miyakawa S, Miyasaka M, Matsuoka K, Okuyama T, Shiohama A, Sasaki T, Kudoh J, Amagai M, Ishiko A: Pathological characterization of pachydermia in pachydermoperiostosis. **J Dermatol 42(7):710-714, 2015.**

4. Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA: Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-gamma. **J Invest Dermatol** 135(11):2775-2784, 2015.
5. Nakamura Y, Kitano S, Takahashi A, Tsutsumida A, Namikawa K, Tanese K, Abe T, Funakoshi T, Yamamoto N, Amagai M et al: Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. **Oncotar** 7(47):77404-77415,2016.
6. Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Jr., Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA: Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. **Clin Can Res** 22(12):3016-3024,2016.
7. Tanese K, Emoto K, Kubota N, Fukuma M, Sakamoto M: Immunohistochemical visualization of the signature of activated Hedgehog signaling pathway in cutaneous epithelial tumors. **J Dermatol** 45(10):1181-1186,2018.
8. Imaoka M, Tanese K, Masugi Y, Hayashi M, Sakamoto M. Macrophage migration inhibitory factor-CD74 interaction regulates the expression of programmed cell death ligand 1 in melanoma cells. **Cancer Sci** 110:2273-2283,2019.
9. Nakamura Y, Tanese K, Hirai I, Amagai M, Kawakami Y, Funakoshi T: Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget's disease. **Br J Dermatol** 181(3):535-543, 2019.
10. Tanese K, Yamori T. Possible Contribution of Drug Approval Summaries Published by Drug Regulatory Authorities on Scientific Discussion and Drug Development. **Clin Pharmacol Drug Dev** 2020,9(1):6-10. doi: 10.1002/cpdd.744.